SS Innovations Completes 500th Successful Surgery Using Flagship Surgical Robotic System

Surgical robotics innovator, SS Innovations International, Inc.  (OTC: SSII) has successfully performed 500 surgeries using its flagship SSi Mantra Surgical Robotic System. The 500th surgery was a complex urology oncology surgery, performed by Dr. Sudhir K. Rawal, Medical Director for Rajiv Gandhi Cancer Institute.

SS Innovations Founder and Chairman, Dr. Sudhir P. Srivastava performed the SSi Mantra’s 501st surgery, a complex heart procedure on a patient with significant coronary artery disease. The bilateral internal mammary artery takedown procedure is the first surgery of its kind to be performed with the SSi Mantra Robotic System.

Dr. Srivastava, said, “It is with great pleasure to realize that from humble beginnings as a company, and through the dedication and effort of our team, along with enormous support from the community of surgeons from all corners of India and the globe, that we have collectively achieved this milestone of 500 successful surgeries using our innovative SSi Mantra System. I am deeply grateful to all who have shared our vision of making Gold Standard Healthcare an affordable and accessible right for the many patients in India who otherwise may not have had access to this level of advanced care. I am thankful to all the doctors and hospitals throughout India who have joined us on this incredible journey of innovation and service.”

Highlights

SS Innovations’ SSi Mantra Surgical Robotic System provides the capabilities for multi-specialty usage including cardiothoracic, head and neck, gynecology, urology, general surgery and more.

The SSi Mantra has been granted regulatory approval in India, the United Arab Emirates and Guatemala, and is clinically validated in more than 40 different types of surgical procedures and 500 surgical procedures have been performed to date. 

About SS Innovations International, Inc.

SS Innovations International, Inc. (OTC: SSII) is a developer of innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger part of the global population. SSII’s product range includes its proprietary “SSi Mantra” surgical robotic system, and “SSi Mudra”, its wide range of surgical instruments capable of supporting a variety of surgical procedures including robotic cardiac surgery. SSII’s business operations are headquartered in India and SSII has plans to expand the presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions, globally. For more information, visit SSII’s website at ssinnovations.com or LinkedIn for updates.

Share this article:

Disclaimer

This communication was produced by Prism MarketView, an affiliate of PCG Advisory Inc., (together “PCG”). PCG is an integrated investor relations, communications and strategic advisory firm. The information contained on this is ‘Paid Advertising’ for purposes of Section 17(b) of the Securities Act of 1933, as amended (together with the rules and regulations there under, the “Securities Act”). “PCG” and its affiliates are compensated by respective clients for publicizing information relating to its client’s securities. For more information in terms of compensation received for services provided by PCG, see the pertinent advertising materials relating to the respective client. By accessing this Site and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy…

Share this article:
Read Full Disclaimer

Share This Article

 

About the Author

SS Innovations Completes 500th Successful Surgery Using Flagship Surgical Robotic System

Catie Corcoran

Biotech Editor